Biomarkers and Immunotherapeutic Targets in Glioblastoma

Alice L. Hung, Tomas Garzon-Muvdi, Michael Lim

Research output: Contribution to journalReview article

Abstract

Glioblastoma (GBM) is an aggressive central nervous system cancer with poor prognosis despite maximal therapy. The recent advent of immunotherapy holds great promise for improving GBM survival and has already made great strides toward changing management strategies. A diverse set of biomarkers have been implicated as immunotherapeutic targets and prognostic indicators in other cancers. Some of the more extensively studied examples include cytokines (IL-4, IL-13, and TGF-β), checkpoint molecules (PD-1, CTLA-4, TIM-3, LAG-3, CD137, GITR, OX40), and growth/angiogenesis proteins (endoglin and EGFR). Emerging theories involving the tumor mutational landscape and microbiome have also been explored in relation to cancer treatment. Although identification of novel biomarkers may improve and help direct treatment of patients with GBM, the next step is to explore the role of biomarkers in precision medicine and selection of specific immunotherapeutic drugs in an individualized manner.

Original languageEnglish (US)
Pages (from-to)494-506
Number of pages13
JournalWorld Neurosurgery
Volume102
DOIs
StatePublished - Jun 1 2017

Fingerprint

Glioblastoma
Biomarkers
Neoplasms
Precision Medicine
Interleukin-13
Microbiota
Interleukin-4
Immunotherapy
Therapeutics
Central Nervous System
Cytokines
Survival
Growth
Pharmaceutical Preparations

Keywords

  • Biomarkers
  • Checkpoint molecules
  • Cytokines
  • Glioblastoma
  • Immunotherapy
  • Microbiome
  • Mutational landscape

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology

Cite this

Biomarkers and Immunotherapeutic Targets in Glioblastoma. / Hung, Alice L.; Garzon-Muvdi, Tomas; Lim, Michael.

In: World Neurosurgery, Vol. 102, 01.06.2017, p. 494-506.

Research output: Contribution to journalReview article

Hung, Alice L. ; Garzon-Muvdi, Tomas ; Lim, Michael. / Biomarkers and Immunotherapeutic Targets in Glioblastoma. In: World Neurosurgery. 2017 ; Vol. 102. pp. 494-506.
@article{8119ba1d0d324374a4f5c95abe71c7cf,
title = "Biomarkers and Immunotherapeutic Targets in Glioblastoma",
abstract = "Glioblastoma (GBM) is an aggressive central nervous system cancer with poor prognosis despite maximal therapy. The recent advent of immunotherapy holds great promise for improving GBM survival and has already made great strides toward changing management strategies. A diverse set of biomarkers have been implicated as immunotherapeutic targets and prognostic indicators in other cancers. Some of the more extensively studied examples include cytokines (IL-4, IL-13, and TGF-β), checkpoint molecules (PD-1, CTLA-4, TIM-3, LAG-3, CD137, GITR, OX40), and growth/angiogenesis proteins (endoglin and EGFR). Emerging theories involving the tumor mutational landscape and microbiome have also been explored in relation to cancer treatment. Although identification of novel biomarkers may improve and help direct treatment of patients with GBM, the next step is to explore the role of biomarkers in precision medicine and selection of specific immunotherapeutic drugs in an individualized manner.",
keywords = "Biomarkers, Checkpoint molecules, Cytokines, Glioblastoma, Immunotherapy, Microbiome, Mutational landscape",
author = "Hung, {Alice L.} and Tomas Garzon-Muvdi and Michael Lim",
year = "2017",
month = "6",
day = "1",
doi = "10.1016/j.wneu.2017.03.011",
language = "English (US)",
volume = "102",
pages = "494--506",
journal = "World Neurosurgery",
issn = "1878-8750",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Biomarkers and Immunotherapeutic Targets in Glioblastoma

AU - Hung, Alice L.

AU - Garzon-Muvdi, Tomas

AU - Lim, Michael

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Glioblastoma (GBM) is an aggressive central nervous system cancer with poor prognosis despite maximal therapy. The recent advent of immunotherapy holds great promise for improving GBM survival and has already made great strides toward changing management strategies. A diverse set of biomarkers have been implicated as immunotherapeutic targets and prognostic indicators in other cancers. Some of the more extensively studied examples include cytokines (IL-4, IL-13, and TGF-β), checkpoint molecules (PD-1, CTLA-4, TIM-3, LAG-3, CD137, GITR, OX40), and growth/angiogenesis proteins (endoglin and EGFR). Emerging theories involving the tumor mutational landscape and microbiome have also been explored in relation to cancer treatment. Although identification of novel biomarkers may improve and help direct treatment of patients with GBM, the next step is to explore the role of biomarkers in precision medicine and selection of specific immunotherapeutic drugs in an individualized manner.

AB - Glioblastoma (GBM) is an aggressive central nervous system cancer with poor prognosis despite maximal therapy. The recent advent of immunotherapy holds great promise for improving GBM survival and has already made great strides toward changing management strategies. A diverse set of biomarkers have been implicated as immunotherapeutic targets and prognostic indicators in other cancers. Some of the more extensively studied examples include cytokines (IL-4, IL-13, and TGF-β), checkpoint molecules (PD-1, CTLA-4, TIM-3, LAG-3, CD137, GITR, OX40), and growth/angiogenesis proteins (endoglin and EGFR). Emerging theories involving the tumor mutational landscape and microbiome have also been explored in relation to cancer treatment. Although identification of novel biomarkers may improve and help direct treatment of patients with GBM, the next step is to explore the role of biomarkers in precision medicine and selection of specific immunotherapeutic drugs in an individualized manner.

KW - Biomarkers

KW - Checkpoint molecules

KW - Cytokines

KW - Glioblastoma

KW - Immunotherapy

KW - Microbiome

KW - Mutational landscape

UR - http://www.scopus.com/inward/record.url?scp=85018500948&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018500948&partnerID=8YFLogxK

U2 - 10.1016/j.wneu.2017.03.011

DO - 10.1016/j.wneu.2017.03.011

M3 - Review article

C2 - 28300714

AN - SCOPUS:85018500948

VL - 102

SP - 494

EP - 506

JO - World Neurosurgery

JF - World Neurosurgery

SN - 1878-8750

ER -